ASCO GI 2021 OS Update: IMbrave150

Ruth He, MD, highlights factors that influence her use of frontline systemic therapy in patients with unresectable hepatocellular carcinoma.

Ruth He, MD, discusses major takeaways from the phase 3 IMbrave150 trial of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Ruth He, MD, discusses the approval of frontline atezolizumab-bevacizumab and its relation to subsequent treatment of patients with unresectable hepatocellular carcinoma.

Ruth He, MD, acknowledges the current struggles experts face in combatting unresectable hepatocellular carcinoma.

Ruth He, MD, discusses potential options for physicians in their treatment of unresectable hepatocellular carcinoma.

Ruth He, MD, grants advice on how to treat patients with unresectable hepatocellular carcinoma.